雲頂新耀-B(01952.HK)公佈2021年全年業績,研發開支增至6.13億元
格隆匯3月29日丨雲頂新耀-B(01952.HK)發佈2021年全年業績公吿,截至2021年12月31日止年度,研發開支由2020年的人民幣3.774億元增加至人民幣6.134億元,主要由於:(i)集團候選藥物的臨牀試驗數量增加;(ii)擴大內部新藥發現團隊以打造內部研發能力;及(iii)集團候選藥物的技術轉讓過程產生的成本增加。該年度的虧損淨額,由2020年的人民幣56.582億元減至人民幣10.087億元,主要由於向投資者發行的金融工具公平值變動產生的虧損減少所致。截至2021年12月31日,現金及現金等價物為人民幣26.401億元。截至2021年12月31日止年度的年內經調整虧損為人民幣7.773億元,較2020年的人民幣6.029億元增加人民幣1.744億元,主要由於研發開支以及分銷及銷售開支增加所致。
集團在業務的各個方面均取得重大進展。2021年,集團繼續以“中國速度和全球質量”推進資產,並授權引進具有全球發展潛力的潛在同類最佳候選藥物,以擴充集團的產品管線。同時,集團擴展了新藥發現、商業化及製造方面的能力,並將公司轉型為一體化的亞洲生物製藥公司。集團的新藥發現團隊不斷壯大,現已搬入位於張江的新研究中心,面積為1,700平方米。其正在開展腫瘤、腎病及mRNA疫苗領域的多個項目。集團已打造一支由領先商業人才組建的商業團隊,其在中國及亞洲的創新藥方面擁有數十年經驗。截至2021年12月31日,該團隊已擴大至128人,並正在就2022年可能上市的多款產品進行準備工作。最後,集團繼續推進浙江嘉善生產基地的建設工作,預期該設施將於2022年投產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.